Deipolyi, Amy R. http://orcid.org/0000-0003-3144-386X
England, Ryan W.
Ridouani, Fourat
Riedl, Christopher C.
Kunin, Henry S.
Boas, F. Edward
Yarmohammadi, Hooman
Sofocleous, Constantinos T.
Funding for this research was provided by:
National Institutes of Health (P30 CA008748)
Article History
Received: 13 January 2020
Accepted: 29 January 2020
First Online: 6 February 2020
Compliance with Ethical Standards
:
: Dr. Deipolyi reports personal fees from BTG, Inc., and personal fees from Dova Pharmaceuticals, outside the submitted work. Dr. Boas is a co-founder of Claripacs, LLC, and received a research grant and supplies from Guerbet, research support from GE, research supplies from Bayer, and a research grant and speaker fees from Society of Interventional Oncology, sponsored by Guerbet; he is also an investor in Labdoor, Qventus, CloudMedx, Notable Labs, and Xgenomes. Dr. Yarmohammadi received research grants from the Thompson Foundation and Guerbet. Dr. Sofocleous received consulting fees from Terumo and consulting fees and research funding from BTG and Johnson and Johnson. The other authors have no disclosures.
Free to read: This content has been made available to all.